J. Safra Sarasin Holding AG Has $1.60 Million Stake in Apellis Pharmaceuticals, Inc. $APLS

J. Safra Sarasin Holding AG lessened its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 39.1% in the third quarter, Holdings Channel.com reports. The firm owned 70,500 shares of the company’s stock after selling 45,184 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Apellis Pharmaceuticals were worth $1,595,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. EFG Asset Management North America Corp. grew its holdings in shares of Apellis Pharmaceuticals by 48.0% during the third quarter. EFG Asset Management North America Corp. now owns 155,399 shares of the company’s stock worth $3,517,000 after purchasing an additional 50,375 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Apellis Pharmaceuticals by 82.5% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 46,113 shares of the company’s stock worth $1,044,000 after buying an additional 20,840 shares during the period. Amalgamated Bank boosted its position in Apellis Pharmaceuticals by 6.9% during the 3rd quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock worth $196,000 after buying an additional 563 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $1,212,000. Finally, Lecap Asset Management Ltd. acquired a new position in Apellis Pharmaceuticals in the 3rd quarter valued at approximately $223,000. 96.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on APLS. Robert W. Baird lifted their price target on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Wall Street Zen raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Stifel Nicolaus cut their target price on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. JPMorgan Chase & Co. decreased their price target on Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Citigroup lowered their price objective on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $33.00.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $23.07 on Thursday. The business has a 50-day moving average price of $23.17 and a two-hundred day moving average price of $23.62. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.10 and a 1-year high of $30.60. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company has a market cap of $2.92 billion, a P/E ratio of 74.42 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same period in the previous year, the business earned ($0.46) EPS. The firm’s revenue was up 133.0% compared to the same quarter last year. As a group, analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 27,192 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $591,969.84. Following the transaction, the chief executive officer directly owned 286,045 shares in the company, valued at approximately $6,227,199.65. This represents a 8.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pascal Deschatelets sold 5,928 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $129,052.56. Following the sale, the insider directly owned 1,151,382 shares of the company’s stock, valued at approximately $25,065,586.14. This trade represents a 0.51% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 125,169 shares of company stock valued at $2,700,681. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.